# Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions

> **NCT03549273** · PHASE2 · UNKNOWN · sponsor: **Catalysis SL** · enrollment: 62 (estimated)

## Conditions studied

- Carcinoma
- Neoplasia; Intraepithelial, Cervix
- Glandular Neoplasms
- Epithelial Neoplasm
- Neoplasms

## Interventions

- **DIETARY_SUPPLEMENT:** Glizigen® + Ocoxin-Viusid®

## Key facts

- **NCT ID:** NCT03549273
- **Lead sponsor:** Catalysis SL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-11
- **Primary completion:** 2024-12-15
- **Final completion:** 2025-01-15
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2024-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03549273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03549273, "Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03549273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*